Previous 10 | Next 10 |
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of agitation associated with schizophrenia and bipolar disorders I & II Dat...
After tripling in 2020, neuroscience-focused biotech BioXcel Therapeutics (NASDAQ: BTAI) has stumbled so far in 2021, losing almost half of its value. While the fall may partially be due to a secondary offering this June , it may also be due to underwhelming results in one o...
NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience...
BioXcel Therapeutics Inc. (NASDAQ:BTAI) traded at a new 52-week low today of $25.86. Approximately 204,000 shares have changed hands today, as compared to an average 30-day volume of 502,000 shares. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on ...
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genuity 41st Annual Growth Conference on...
Shares of BioXcel Therapeutics Inc. (NASDAQ:BTAI) traded at a new 52-week low today of $26.22. So far today approximately 204,000 shares have been exchanged, as compared to an average 30-day volume of 473,000 shares. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company....
BioXcel Therapeutics Inc. (NASDAQ:BTAI) traded today at a new 52-week low of $26.67. So far today approximately 204,000 shares have been exchanged, as compared to an average 30-day volume of 448,000 shares. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is foc...
BioXcel Therapeutics Inc. (NASDAQ:BTAI) traded at a new 52-week low today of $26.87. So far today approximately 204,000 shares have been exchanged, as compared to an average 30-day volume of 441,000 shares. In the past 52 weeks, shares of BioXcel Therapeutics Inc. have traded between the...
Shares of BioXcel Therapeutics Inc. (NASDAQ:BTAI) traded at a new 52-week low today of $27.31. Approximately 204,000 shares have changed hands today, as compared to an average 30-day volume of 272,000 shares. Potential upside of 25.5% exists for BioXcel Therapeutics Inc., based on a curr...
Shares of BioXcel Therapeutics (NASDAQ: BTAI) , a clinical-stage biotechnology company, fell hard this week as shareholders responded to a secondary share offering. Since the market closed last Friday, the biotech stock has lost around 16.8% of its value. On June 23, 2021, B...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...